-
Patients warned of clinical differences in thyroid meds; Higher costs affect MS patients adherence to medications; FDA issues warnings, label changes; Survey highlights importance of pharmacist/patient relationship.
-
Pentetate calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA) by Hameln Pharmaceuticals, GmbH, of Hameln, Germany.
-
Now that the National Cholesterol Education Program has updated its clinical practice guidelines on cholesterol management, one of the questions is how health care providers can reach the lower treatment goals for low-density lipoprotein (LDL) cholesterol for patients at high and moderately high risk of a heart attack.
-
Rosuvastatin calcium (Crestor) just passed its one-year anniversary since being approved by the U.S. Food and Drug Administration (FDA). Although by reports it has generated almost $4 billion in annual sales for AstraZeneca, the approval initially brought mixed feelings for many physicians, says Peter H. Jones, MD.
-
Apomorphine was recognized in 1960 to affect dopamine receptors in the treatment of Parkinsons disease (PD). The U.S. Food and Drug Administration (FDA) designated apomorphine as an orphan drug in 1991 for the treatment of hypomobility in idiopathic stage intravenous (IV) PD patients.
-
-
-
Drawing upon a real-world lesson from the past, medical toxicologists recently recalled the 1983 Tylenol poisoning case in Chicago as an example of how a bioterrorism attack involving chemicals may begin to unfold. Though product-tampering protections have been improved, disturbing aspects of the case include how easy it was to accomplish and the fact that the perpetrator was never caught.
-
The Agency for Healthcare Research and Quality (AHRQ) has created a tool to help state and local officials quickly locate alternate health care sites if hospitals are overwhelmed by patients due to a bioterrorism attack or other public health emergency.
-
The massive public health investment to prepare for bioterrorism is paying for itself in the widespread benefits of an improved public health infrastructure, said Julie Gerberding, MD, MPH, director of the Centers for Disease Control and Prevention.
